Clinical Indication ID & Name
Uterine Sarcomas (Inc Endometrial)
Test Group
Sarcomas
Specialties
Test code
M203.1
Test name
EPC1-PHF1 rearrangement FISH
Target genes
EPC1-PHF1
Test scope
Structural variant detection
Test method/ technology
FISH
Optimal Family Structure
n/a
Eligibility Criteria
Specialist sarcoma pathology review indicates that molecular assessment will aid diagnosis or management
Test code
M203.2
Test name
JAZF1-PHF1 rearrangement FISH
Target genes
JAZF1-PHF1
Test scope
Structural variant detection
Test method/ technology
FISH
Optimal Family Structure
n/a
Eligibility Criteria
Specialist sarcoma pathology review indicates that molecular assessment will aid diagnosis or management
Test code
M203.3
Test name
JAZF1-SUZ12 rearrangement FISH
Target genes
JAZF1-SUZ12
Test scope
Structural variant detection
Test method/ technology
FISH
Optimal Family Structure
n/a
Eligibility Criteria
Specialist sarcoma pathology review indicates that molecular assessment will aid diagnosis or management
Test code
M203.4
Test name
NUTM2B-YWHAE FISH/RT-PCR
Target genes
NUTM2B-YWHAE
Test scope
Structural variant detection
Test method/ technology
FISH/Simple targeted mutation testing
Optimal Family Structure
n/a
Eligibility Criteria
Specialist sarcoma pathology review indicates that molecular assessment will aid diagnosis or management
Test code
M203.5
Test name
WGS Germline and Tumour
Target genes
All including burden / signature
Test scope
All variant types
Test method/ technology
WGS
Optimal Family Structure
n/a
Eligibility Criteria
Specialist sarcoma pathology review indicates that molecular assessment will aid diagnosis or management
Test code
M203.6
Test name
Multi-target NGS panel - structural variant (EPC1-PHF1, JAZF1-PHF1, JAZF1-SUZ12, NUTM2B-YWHAE, NTRK1, NTRK2, NTRK3)
Target genes
EPC1-PHF1, JAZF1-PHF1, JAZF1-SUZ12, NUTM2B-YWHAE, NTRK1, NTRK2, NTRK3
Test scope
Structural variant detection
Test method/ technology
Panel
Optimal Family Structure
n/a
Eligibility Criteria
Specialist sarcoma pathology review indicates that molecular assessment will aid diagnosis or management / Patient’s clinical status means they are eligible for an NTRK inhibitor in the event an NTRK rearrangement is detected
Commissioning group
n/a
Overlapping idications
n/a
Address for samples/request forms
North Thames GLH, Rare & Inherited Disease Genomic Laboratory
Specimen Reception, Level 5 Barclay House, 37 Queen Square,
London WC1N 3BH
Contact with queries
Supporting documents
Cancer WGS Clinician pack
Education resources
n/a
Service updates
n/a
Request form download
n/a
Consent record
See consent guidance in test request form
Sample requirements
See sample guidance in test request form